학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 1,066건 | 목록 1~20
Academic Journal
Luciano-Mateo F; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Moreno-Caceres J; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Hernández-Madrigal M; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Püschel F; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Collado-Rodriguez L; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Favaro F; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Hijazo-Pechero S; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Cruz-Rodríguez M; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Jiménez-Hernández F; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Villagrasa-Araya V; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Figueras-Duch N; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Redondo-Pedraza J; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Palau-Gallinat D; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Plans-Marin S; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Figueras A; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.; Fuentes Varela P; Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; de Benito-Gómez L; Physiological Sciences Department, University of Barcelona, Campus de Bellvitge, L'Hospitalet de Llobregat, Spain.; Nutrition, Metabolism and Gene Therapy Group, Diabetes and Metabolism Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Gentilella A; Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.; Perales JC; Physiological Sciences Department, University of Barcelona, Campus de Bellvitge, L'Hospitalet de Llobregat, Spain.; Solé X; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Molecular Biology CORE, Center for Biomedical Diagnostics, Hospital Clínic i Provincial de Barcelona, IDIBAPS, Barcelona, Spain.; Méndez-Lucas A; Physiological Sciences Department, University of Barcelona, Campus de Bellvitge, L'Hospitalet de Llobregat, Spain.; Nutrition, Metabolism and Gene Therapy Group, Diabetes and Metabolism Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Viñals F; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.; Physiological Sciences Department, University of Barcelona, Campus de Bellvitge, L'Hospitalet de Llobregat, Spain.; Nadal E; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.; Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain.; Muñoz-Pinedo C; Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. cmunoz@idibell.cat.
Publisher: Springer Nature Country of Publication: Germany NLM ID: 101736592 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2522-5812 (Electronic) Linking ISSN: 25225812 NLM ISO Abbreviation: Nat Metab Subsets: MEDLINE; In Process
Academic Journal
Espín R; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Medina-Jover F; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Department of Physiological Sciences, University of Barcelona, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Sigüenza-Andrade J; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Farran-Matas S; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Mateo F; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Figueras A; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Sanz RT; Molecular Biology Institute of Barcelona, Spanish National Research Council (IBMB-CSIC), Barcelona 08028, Spain.; Vicent GP; Molecular Biology Institute of Barcelona, Spanish National Research Council (IBMB-CSIC), Barcelona 08028, Spain.; Shabbir A; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Ruiz-Auladell L; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Racionero-Andrés E; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; García I; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Baiges A; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Franco-Luzón L; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Martínez-Tebar A; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Pardo-Cea MA; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Martínez-Iniesta M; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Wang XC; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Cuyàs E; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Girona Biomedical Research Institute (IDIBGI), Salt, Girona 17190, Spain.; Menendez JA; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Girona Biomedical Research Institute (IDIBGI), Salt, Girona 17190, Spain.; Lopez-Cerda M; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Muñoz P; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Richaud I; Regenerative Medicine Program and Program for Clinical Translation of Regenerative Medicine in Catalonia-P-CMR[C], Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Biomedical Research Network Centre in Bioengineering, Nanomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid 28029, Spain.; Raya A; Regenerative Medicine Program and Program for Clinical Translation of Regenerative Medicine in Catalonia-P-CMR[C], Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Biomedical Research Network Centre in Bioengineering, Nanomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid 28029, Spain.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona 08010, Spain.; Fabregat I; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Biomedical Research Networking Centre in Hepatic and Digestive Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid 28029, Spain.; Villanueva A; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Serrat X; Modeling Human Diseases in C. elegans Group, Genes, Diseases, and Therapies Program, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Cerón J; Modeling Human Diseases in C. elegans Group, Genes, Diseases, and Therapies Program, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Alemany M; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Neuro-Oncology Unit, University Hospital of Bellvitge, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Guix I; Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Centre, University of California San Francisco, San Francisco, CA 94115, United States.; Herencia-Ropero A; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona 08193, Spain.; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.; Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.; Krishnan R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.; Mekhail K; Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.; Hakem R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 1A8, Canada.; Bruna J; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Neuro-Oncology Unit, University Hospital of Bellvitge, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Barcellos-Hoff MH; Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Centre, University of California San Francisco, San Francisco, CA 94115, United States.; Viñals F; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Department of Physiological Sciences, University of Barcelona, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Aytes Á; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Pujana MA; ProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.; Girona Biomedical Research Institute (IDIBGI), Salt, Girona 17190, Spain.
Publisher: Oxford University Press Country of Publication: England NLM ID: 101769553 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8674 (Electronic) Linking ISSN: 26328674 NLM ISO Abbreviation: NAR Cancer Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Viñals, F.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어